Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease

Clenbuterol, a β2-adrenergic agonist, reciprocally alters PGC-1 alpha and RIP140 and reduces fatty acid and pyruvate oxidation in rat skeletal muscle

(2011) Daisuke Hoshino et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Transport of Arylsulfatase A across the Blood-Brain Barrierin Vitro

(2011) Frank Matthes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle

(2011) Dwight D. Koeberl et al.   MOLECULAR GENETICS AND METABOLISM

β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease

(2011) Dwight D. Koeberl et al.   MOLECULAR GENETICS AND METABOLISM

Clinical and Histologic Ocular Findings in Pompe Disease

(2010) Tammy L. Yanovitch et al.   JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS

Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: From our experience of 4 cases including an autopsy case

(2010) Hiroshi Kobayashi et al.   MOLECULAR GENETICS AND METABOLISM

Gel-mediated Delivery of AAV1 Vectors Corrects Ventilatory Function in Pompe Mice With Established Disease

(2010) Cathryn S Mah et al.   MOLECULAR THERAPY

New Strategies for Enzyme Replacement Therapy for Lysosomal Storage Diseases

(2010) Jeffrey H. Grubb et al.   REJUVENATION RESEARCH

Oropharyngeal Dysphagia in Infants and Children with Infantile Pompe Disease

(2009) Harrison N. Jones et al.   DYSPHAGIA

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

(2009) Marc Nicolino et al.   GENETICS IN MEDICINE

Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression

(2009) Baodong Sun et al.   JOURNAL OF GENE MEDICINE

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial

(2009) S. Strothotte et al.   JOURNAL OF NEUROLOGY

Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease

(2009) Yunxiang Zhu et al.   MOLECULAR THERAPY

Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease

(2009) Baodong Sun et al.   MOLECULAR THERAPY

Clenbuterol Increases Lean Muscle Mass but Not Endurance in Patients With Chronic Heart Failure

(2008) Gayathri Kamalakkannan et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe disease

(2008) A.J. McVie-Wylie et al.   MOLECULAR GENETICS AND METABOLISM

AAV Vector-mediated Reversal of Hypoglycemia in Canine and Murine Glycogen Storage Disease Type Ia

(2008) Dwight D Koeberl et al.   MOLECULAR THERAPY

The potential and the pitfalls of β-adrenoceptor agonists for the management of skeletal muscle wasting

(2008) James G. Ryall et al.   PHARMACOLOGY & THERAPEUTICS

Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease

(2008) Gordon S. Lynch et al.   PHYSIOLOGICAL REVIEWS

Signaling in Muscle Atrophy and Hypertrophy

(2008) Marco Sandri   PHYSIOLOGY